Immutep (Immutep) Beginning Cash Position

: $73.72 Mil (As of Dec. 2023)

View and export this data going back to 1988. Start your Free Trial

Immutep's Beginning Cash Position for the quarter that ended in Dec. 2023 was $73.72 Mil.

Immutep's quarterly Beginning Cash Position increased from Jun. 2023 ($37.05 Mil) to Sep. 2023 ($79.32 Mil) but then declined from Sep. 2023 ($79.32 Mil) to Dec. 2023 ($73.72 Mil).

Immutep's annual Beginning Cash Position increased from Jun. 2021 ($20.12 Mil) to Jun. 2022 ($42.58 Mil) and increased from Jun. 2022 ($42.58 Mil) to Jun. 2023 ($53.69 Mil).

Immutep Beginning Cash Position Historical Data

The historical data trend for Immutep's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Beginning Cash Position

16.30

11.43

20.12

42.58

53.69

Immutep Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beginning Cash Position																49.89	45.65	37.05	79.32	73.72

Immutep Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Immutep Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Immutep's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep (Immutep) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (NAS:IMMP) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

PRRUF:USA YP1B:Germany IMM:Australia

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.